title: Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?
authors.forename: Adriana
authors.initials: A
authors.lastname: Franzese
authors.forename: Maria Immacolata
authors.initials: MI
authors.lastname: Spagnuolo
authors.forename: Angela
authors.initials: A
authors.lastname: Sepe
authors.forename: Giuliana
authors.initials: G
authors.lastname: Valerio
authors.forename: Enza
authors.initials: E
authors.lastname: Mozzillo
authors.forename: Valeria
authors.initials: V
authors.lastname: Raia
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology*; D005541:Forced Expiratory Volume; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008168:Lung / Q000187:drug effects / Q000503:physiopathology*; D017384:Sequence Deletion
chemical_list: C505032:CFTR protein, human; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D000069036:Insulin Glargine